Aerovate Therapeutics Inc

NASDAQ AVTE

Download Data

Aerovate Therapeutics Inc Invested Capital for the year ending December 31, 2023: USD 110.20 M

Aerovate Therapeutics Inc Invested Capital is USD 110.20 M for the year ending December 31, 2023, a -13.84% change year over year. Invested capital represents the total amount of capital invested in a company's operations, including both equity and debt. It is calculated by subtracting the sum of current liabilities (excluding short-term debt) from the total assets of a company. Invested capital reflects the long-term financial resources employed in the company's operations. It is an important measure to evaluate a company's capital structure and assess the amount of capital invested in its productive assets.
  • Aerovate Therapeutics Inc Invested Capital for the year ending December 31, 2022 was USD 127.90 M, a -26.07% change year over year.
  • Aerovate Therapeutics Inc Invested Capital for the year ending December 31, 2021 was USD 173.00 M.
NASDAQ: AVTE

Aerovate Therapeutics Inc

CEO Mr. Timothy P. Noyes M.B.A.
IPO Date June 30, 2021
Location United States
Headquarters 930 Winter Street, Waltham, MA, United States, 02116
Employees 51
Sector Healthcare
Industry Biotechnology
Description

Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. The company was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

Similar companies

ADAG

Adagene Inc

NA

NA

ACRV

Acrivon Therapeutics Inc. Common Stock

NA

NA

ANTX

AN2 Therapeutics Inc

NA

NA

ANEB

Anebulo Pharmaceuticals Inc

NA

NA

StockViz Staff

September 20, 2024

Any question? Send us an email